| 產(chǎn)品名稱 |
WIL2-S |
| 商品貨號(hào) |
B165950 |
| Organism |
Homo sapiens, human |
| Tissue |
spleen |
| Cell Type |
B lymphoblast |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
suspension |
| Biosafety Level |
2 [Cells contain Epstein-Barr virus]
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease |
hereditary spherocytosis |
| Age |
5 years |
| Gender |
male |
| Ethnicity |
Caucasian |
| Applications |
This cell line is a suitable transfection host. |
| Storage Conditions |
liquid niotrogen vapor phase |
| Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
| Clinical Data |
5 years Caucasian male |
| Comments |
This is a HAT sensitive variant of the WIL2 human B cell line (see also ATCC CRL-8155). |
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing |
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 105 cells/mL and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/mL.
Medium Renewal: Every 2 to 3 days |
| STR Profile |
Amelogenin: X,Y CSF1PO: 11,12 D13S317: 11 D16S539: 11,12 D5S818: 12,13 D7S820: 9,11 F13A01: 6,7 F13B: 10 FESFPS: 11,12 LPL: 9,10 THO1: 8,9.3 TPOX: 8,11 vWA: 17,20 |
| Name of Depositor |
Lovelace Medical Foundation |
| Deposited As |
Homo sapiens |
| U.S. Patent Number |
|
